Abstract
Diabetes mellitus is a lifelong, incapacitating disease affecting multiple organs. Presently, type 2 diabetes (T2D) can neither be prevented nor cured and the disease is associated with devastating chronic complications. These complications impose an immense burden on the quality of life of patients and account for about 12% of direct health care costs in Europe. Genetic analysis will increase our understanding of this heterogeneous disease and may help offer more personalized treatment.
Copyright © 2014 Elsevier Ltd. All rights reserved.
MeSH terms
-
Biological Availability
-
Diabetes Mellitus, Type 1 / drug therapy
-
Diabetes Mellitus, Type 1 / genetics*
-
Diabetes Mellitus, Type 1 / metabolism
-
Diabetes Mellitus, Type 2 / drug therapy
-
Diabetes Mellitus, Type 2 / genetics*
-
Diabetes Mellitus, Type 2 / metabolism
-
Dipeptidyl-Peptidase IV Inhibitors / adverse effects
-
Dipeptidyl-Peptidase IV Inhibitors / pharmacokinetics
-
Dipeptidyl-Peptidase IV Inhibitors / therapeutic use
-
Genetic Variation*
-
Humans
-
Hypoglycemic Agents / adverse effects
-
Hypoglycemic Agents / pharmacokinetics*
-
Hypoglycemic Agents / therapeutic use
-
Intestinal Absorption
-
Metformin / adverse effects
-
Metformin / pharmacokinetics
-
Metformin / therapeutic use
-
Pharmacogenetics / methods*
-
Precision Medicine*
-
Sulfonylurea Compounds / adverse effects
-
Sulfonylurea Compounds / pharmacokinetics
-
Sulfonylurea Compounds / therapeutic use
-
Thiazolidinediones / adverse effects
-
Thiazolidinediones / pharmacokinetics
-
Thiazolidinediones / therapeutic use
Substances
-
Dipeptidyl-Peptidase IV Inhibitors
-
Hypoglycemic Agents
-
Sulfonylurea Compounds
-
Thiazolidinediones
-
Metformin